timothy sykes logo
RARE Stock Collapses As Angelman Trial Failure Triggers Downgrades Thumbnail
G Google News

RARE Stock Collapses As Angelman Trial Failure Triggers Downgrades

JACK KELLOGG•UPDATED SEP. 3, 2026, 8:33 AM ET
Reviewed by Tim Sykesand Fact-checked by Ellis Hobbs

Ultragenyx Pharmaceutical Inc. stocks have been trading down by -46.93 percent amid heightened concerns over its clinical trial setbacks.

Key Takeaways

  • Ultragenyx’s Phase 3 Aspire trial of apazunersen (GTX-102) in Angelman syndrome failed to meet its primary cognitive endpoint and key secondary MDRI endpoint.
  • Following the failed Phase 3 study, shares plunged about 45% to $14.50, signaling a major setback for RARE’s lead pipeline asset and future revenue potential.
  • The company plans significant expense reductions and is reevaluating apazunersen while leaning more on its rare-disease commercial portfolio and reiterating a goal of profitability by 2027.
  • William Blair downgraded RARE from Outperform to Market Perform after the study failure, citing doubts about the related Aurora study of GTX-102 and limited near-term value catalysts.
  • Evercore ISI downgraded RARE to In Line from Outperform and cut its price target to $16 from $34, pointing to a heavy expense burden, future Crysvita loss of exclusivity, and reliance on first‑generation AAV gene therapies.

Candlestick Chart

Live Update At 08:32:36 EDT: On Thursday, September 03, 2026 Ultragenyx Pharmaceutical Inc. stock [NASDAQ: RARE] is trending down by -46.93%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Ultragenyx Pharmaceutical Inc., ticker RARE, just went from a slow grind to a violent reset. Before the Angelman news, RARE had been chopping in the mid‑$20s. The daily chart shows closes mostly between $25 and $27 over the last couple of weeks, a tight range for a volatile biotech name.

Now the stock is trading near $14.50, meaning the market has essentially sliced RARE’s value in half overnight. For traders, that’s not just a dip. That’s a full repricing of the company’s pipeline risk.

On the fundamentals, RARE is still a classic high-growth, high-burn biotech story. Quarterly revenue is about $214M, with trailing revenue near $673M and strong 87.8% gross margins. But RARE is spending aggressively: research expense sits around $167M for the quarter, with total operating expenses of $255M and a net loss of about $92M.

More Breaking News

Cash is meaningful at $140M at quarter end, plus short-term investments for total liquidity around $292M, and a current ratio of 1.7. Still, operating cash flow is negative $97M for the quarter. For traders, that means RARE is a loss-making name relying on its rare-disease portfolio and future approvals to reach the 2027 profitability target management keeps talking about.

Why Traders Are Watching RARE After The Plunge

RARE is on every momentum trader’s screen because this is the kind of binary biotech event that rewrites the story in a single headline. The Phase 3 Aspire trial of apazunersen (also called GTX‑102) in Angelman syndrome missed both its main cognitive endpoint and the key secondary MDRI endpoint. That is not a soft miss. For RARE, this was one of the lead pipeline assets expected to drive future growth.

The reaction was brutal and fast. RARE dropped roughly 45% after the news, landing near $14.50. Intraday five‑minute data show heavy premarket trading in the mid‑$14s, with quick spikes toward $15 and just as quick fades. That kind of action tells traders the market is trying to find a new equilibrium while short‑term players scalp the volatility.

RARE management responded by launching a strategic review of the apazunersen program and openly considering whether to continue or terminate it. At the same time, Ultragenyx is talking about “significant expense reductions” and a pivot toward its commercial rare-disease portfolio, including products like GENGLYCOS and a potential UX111 approval. The company is still publicly targeting profitability in 2027, but after this trial failure, traders will treat that as a statement to test, not a given.

Wall Street added pressure. William Blair cut RARE to Market Perform, flagging that the Angelman failure also clouds the related Aurora study of GTX‑102 and drains near-term catalysts. Evercore ISI went further, downgrading RARE to In Line and slashing its target to $16 from $34, highlighting heavy expenses, a future loss of exclusivity for Crysvita, and reliance on first‑generation AAV gene therapies in small markets. For active traders, that means the bounce potential in RARE is fighting not just a bad headline, but a wall of lowered expectations.

Conclusion

For Ultragenyx and RARE, the failed Phase 3 Angelman study is more than one bad data readout. It strikes at the heart of a key growth pillar and forces a reset of how the market values the entire pipeline. The stock collapsing about 45% to the mid‑$14s tells you traders are now pricing RARE as a risk-heavy commercial rare-disease platform with a wounded late‑stage pipeline, not a clean growth story.

At the same time, RARE still has real revenue, high gross margins, and a growing portfolio that management wants to lean on while cutting expenses. The 2027 profitability goal is still on the table, but the path just got narrower. Analyst downgrades from William Blair and Evercore show that institutional money is stepping back until RARE proves it can manage costs, replace lost pipeline value, and navigate looming Crysvita competition.

For day traders and swing traders, this is a classic “broken story, big range” setup. Liquidity is high, emotions are high, and the chart is wild. As Tim Sykes likes to say, “Volatility is opportunity for prepared traders, but a trap for everyone else.” As millionaire penny stock trader and teacher Tim Sykes, says, “You must adapt to the market; the market will not adapt to you.”. RARE now demands exactly that kind of preparation — tight risk management, clear levels, and zero hesitation to cut losses fast. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”